The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 2 , Pages 255-260 , February 2008

MicroRNA expression profiles of esophageal cancer

  • Andrew Feber, PhD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, NY
    • ,
  • Liqiang Xi, MD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, NY
    • ,
  • James D. Luketich, MD

      Affiliations

    • Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa
    • ,
  • Arjun Pennathur, MD

      Affiliations

    • Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa
    • ,
  • Rodney J. Landreneau, MD

      Affiliations

    • Heart, Lung and Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa
    • ,
  • Maoxin Wu, MD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, NY
    • ,
  • Scott J. Swanson, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY
    • ,
  • Tony E. Godfrey, PhD

      Affiliations

    • Department of Pathology, Mount Sinai Medical Center, New York, NY
    • ,
  • Virginia R. Litle, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Mount Sinai Medical Center, New York, NY
    • Corresponding Author InformationAddress for reprints: Virginia R. Litle, MD, Division of Thoracic Surgery, Mount Sinai Medical Center, 1190 Fifth Ave, Box 1028, New York, NY 10029.

Received 4 May 2007 ,Revised 12 August 2007 ,Accepted 15 August 2007.

References 

  1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  2. Gamliel Z, Krasna MJ. Multimodality treatment of esophageal cancer. Surg Clin North Am. 2005;85:621–630
  3. Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS, Litle VR, et al. Minimally invasive esophagectomy—outcomes in 222 patients. Ann Surg. 2003;238:486–494
  4. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg. 2001;72:1918–1924
  5. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164:1482–1488
  6. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99:860–868
  7. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053
  8. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831
  9. Csendes A, Smok G, Burdiles P, Quesada F, Huertas C, Rojas J, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus. 2000;13:5–11
  10. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972–1981
  11. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol. 1997;13:270–280
  12. Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176
  13. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg. 1996;224:66–71
  14. Nigro JJ, Hagen JA, DeMeester TR, DeMeester SR, Theisen J, Peters JH, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg. 1999;230:433–438
  15. Tharavej C, Hagen JA, Peters JH, Portale G, Lipham J, DeMeester SR, et al. Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc. 2006;20:439–443
  16. Larghi A, Lightdale CJ, Memeo L, Bhagat G, Okpara N, Rotterdam H. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc. 2005;62:16–23
  17. Sharma VK, Wang KK, Overholt BF, Lightdale CJ, Fennerty MB, Dean PJ, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195
  18. Korst RJ, Altorki NK. High grade dysplasia: surveillance, mucosal ablation, or resection?. World J Surg. 2003;27:1030–1034
  19. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA. 2002;287:1982–1986
  20. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol. 1988;19:166–178
  21. Lee RC, Feinbaum RL, Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854
  22. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269
  23. Lu J, Getz G, Miska EA, varez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838
  24. Calin GA, Ferracin M, Cimmino A, Di LG, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–1801
  25. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–7070
  26. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–198
  27. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24
  28. Selaru FM, Zou T, Xu Y, Shustova V, Yin J, Mori Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2002;21:475–478
  29. Helm J, Enkemann SA, Coppola D, Barthel JS, Kelley ST, Yeatman TJ. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res. 2005;11:2478–2485
  30. Watson DI, Wijnhoven BP, Michael MZ, Mayne GC, Hussey DJ. Hp24 microRNA expression profiles in Barrett's oesophagus. ANZ J Surg. 2007;77(Suppl 1):A45
  31. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–193
  32. Cameron AJ. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus. 2002;15:106–108
  33. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene. 2006;25:3346–3356
  34. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001;98:15149–15154
  35. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005;102:19075–19080
  36. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–2261
  37. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029–6033
  38. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290–1297

PII: S0022-5223(07)01639-X

doi: 10.1016/j.jtcvs.2007.08.055

The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 2 , Pages 255-260 , February 2008

Article Tools

* Image Usage & Resolution